Stocks and Investing Stocks and Investing
Thu, March 16, 2023

Serge Belanger Maintained (ARQT) at Strong Buy with Decreased Target to $24 on, Mar 16th, 2023


Published on 2024-10-28 02:17:37 - WOPRAI, Serge Belanger
  Print publication without navigation


Serge Belanger of Needham, Maintained "Arcutis Biotherapeutics, Inc." (ARQT) at Strong Buy with Decreased Target from $46 to $24 on, Mar 16th, 2023.

Serge has made no other calls on ARQT in the last 4 months.



There is 1 other peer that has a rating on ARQT. Out of the 1 peers that are also analyzing ARQT, 0 agree with Serge's Rating of Hold.



This is the rating of the analyst that currently disagrees with Serge


  • Vikram Purohit of "Morgan Stanley" Maintained at Buy with Decreased Target to $50 on, Wednesday, March 1st, 2023

Contributing Sources